Correction to: Impact of risk minimisation measures on the use of strontium ranelate in Europe: a multi-national cohort study in 5 EU countries by the EU-ADR Alliance

Osteoporos Int. 2020 Apr;31(4):799. doi: 10.1007/s00198-020-05314-2.

K Berencsi^{1

2}, A Sami², M S Ali^{2

3}, K Marinier⁴, N Deltour⁴, S Perez-Gutthann⁵, L Pedersen¹, P Rijnbeek⁶, J Van der Lei⁶, F Lapi⁷, M Simonetti⁷, C Reyes⁸, M C J M Sturkenboom⁹, D Prieto-Alhambra^{10

11

12}

¹ Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark.
² Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.
³ Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
⁴ Department of Pharmacoepidemiology, Servier, Suresnes, France.
⁵ RTI Health Solutions, Barcelona, Spain.
⁶ Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.
⁷ Health Search, Italian College of General Practitioners and Primary Care, Florence, Italy.
⁸ GREMPAL Research Group, Idiap Jordi Gol Primary Care Research Institute and CIBERFes, Universitat Autonoma de Barcelona and Instituto de Salud Carlos III, Barcelona, Spain.
⁹ Julius Global Health, University Medical Center, Utrecht, The Netherlands.
¹⁰ Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK. Daniel.prietoalhambra@ndorms.ox.ac.uk.
¹¹ GREMPAL Research Group, Idiap Jordi Gol Primary Care Research Institute and CIBERFes, Universitat Autonoma de Barcelona and Instituto de Salud Carlos III, Barcelona, Spain. Daniel.prietoalhambra@ndorms.ox.ac.uk.
¹² Botnar Research Centre, Oxford, UK. Daniel.prietoalhambra@ndorms.ox.ac.uk.

Abstract

The original version of this article, published on 26 November 2019 contained a mistake.